Drug Discovery

Boehringer, Tsinghua University to develop immunological therapies for infectious diseases

German pharma company Boehringer Ingelheim has announced a collaboration with Tsinghua University in Beijing to research and develop immunological therapies for infectious diseases.

Evotec, CHDI Foundation expand collaboration for Huntington’s disease

CHDI Foundation has extended its collaboration with Evotec through to 2023 to fight against Huntington's disease, a familial disease caused by a mutation in the huntingtin gene.

Data science company IXICO extends contract with biopharmaceutical firm

IXICO, the data science company offering insights in neuroscience, has signed a further change order to a current contract which increases the total contract value to €1.3m.

KaNDy Therapeutics raises £25m to advance non-hormonal drug candidate

KaNDy Therapeutics, a UK-based clinical stage company focused on women’s health, has raised £25m in a Series C financing round.

Genentech, Affimed sign $5bn cancer deal

Roche Group’s member Genentech has collaborated with Affimed for the development and commercialization of NK cell engager-based immunotherapeutics for multiple cancer targets.

Harbour BioMed raises $85m to accelerate growth of therapeutic pipeline

Biopharmaceutical company Harbour BioMed has secured $85m series B financing to advance the growth of its therapeutic pipeline, including both clinical and discovery stage programs.

JWP out-licenses atopic dermatitis drug JW1601 to LEO in $402m deal

South Korea-based JW Pharmaceutical (JWP) has entered into a global licensing agreement with LEO Pharma whereby the former will grant the latter's exclusive rights to develop and commercialize its atopic dermatitis drug JW1601 in a deal that could reach KRW450bn ($402m).

bluebird bio, Gritstone partner to develop cancer cell therapies

bluebird bio and Gritstone Oncology have partnered to research, develop and commercialize products for the treatment of cancer using cell therapy.

ApoGen Biotechnologies expands series A financing to $11m

ApoGen Biotechnologies, a biotechnology firm engaged in the development of a new class of therapeutics targeting drivers of cancer genomic mutations, has expanded its series A financing to a total of $11m.